Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology
(TheNewswire)
Key Highlights
PositiveFirst-in-Human Results: Three-month Group1 data met or exceeded expectations for safety, lens delivery, andvision performance.
Major De-RiskingMilestone: The study successfullyvalidated the core technology and cleared the path to the nextclinical phase.
Life-Changing VisionImprovements: Patients with severe visionloss experienced meaningful improvements in everyday vision.
Strong ForwardMomentum: Planning for Group 2 surgeriesis underway, with lens and delivery enhancements already indevelopment.
High Confidence GoingForward: Management remains fullyconfident in the Ocumetics accommodating intraocular lens platformfollowing these results.
Calgary, Alberta – February 3,2026 – TheNewswire -Ocumetics Technology Corp. (“Ocumetics”or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leaderin next generation ophthalmic technology, today announced positivethree-month postoperative results from Group 1 patients in itsfirst-in-human (FIH) clinical study of the Ocumetics AccommodatingIntraocular Lens (the “Ocumetics Lens”). The results validate theCompany’s core technology and represent a key clinical de-riskingmilestone as Ocumetics advances toward subsequent studyphases.
The Group 1 data met or exceeded all predefinedinternal benchmarks for safety, lens delivery, and foundationaldistance visual performance - successfully achieving the primaryobjectives required to progress the clinical program.
“These first-in-human results are exactly what wewere aiming to demonstrate at this stage: safe implantation, reliabledelivery, and strong visual outcomes,” said Dean Burns, Presidentand CEO of Ocumetics. “Following a detailedreview of the data with Dr. Raphael Vasquez, our primary surgeon, Iremain 100% confident in our accommodating intraocular lenstechnology. Based on this success, we have initiated planning forGroup 2 surgeries.”
Clinical Validation and MeaningfulPatient Impact
Group 1 patients entered the study with severe visualimpairment, with some presenting uncorrected preoperative acuities aspoor as 20/250 - levels consistent with legal blindness.Post-implantation outcomes underscore both the clinical effectivenessand real-world impact of the Ocumetics Lens.
“All patient outcomes have met safetyexpectations,” said Dr. Rafael Vázquez MD, principal investigatorof the Ocumetics first-in-human trial. “The profile of thepatients I selected had poor vision, and as aresult of the implantations, they have experienced truly a lifechanging event. From being classified legally blind, my patients cannow read, enjoy everyday life activities, and drive. The impact ontheir independence and sense of freedom has been remarkable,” addsDr. Vázquez.
The results from Group 1 can be best summarizedas:
• Safety profile met expectations
• Visual acuity outcomes met and exceededexpectations
• Lens delivery system met expectations
Accelerated Path Forward
Ocumetics continues to apply its rapid “win-learn”R&D approach, incorporating surgeon feedback in real time tofurther optimize performance. Based on insights from Group 1, theCompany has already implemented refinements to the lens deliverymechanism and initiated multiple lens optimization initiatives aimedat enhancing outcomes in Group 2.
Manufacturing and testing of optimized lens designs arecurrently underway. Group 2 surgeries are expected to be scheduledfollowing completion of final lens testing and validation.
“Our Group 1 results clearly demonstrated andconfirmed the viability of our accommodating intraocular lenstechnology,” concluded Burns. “This milestone materiallystrengthens our clinical foundation and positions Ocumetics to buildmomentum as we advance into Group 2. We are excited to continueexecuting on our clinical and development roadmap.”
Ocumetics Webinar
Join Ocumetics Director and CEO, Dean Burns, for anexclusive webinar covering our three-month study results and importantupdates on our FIH study.
Date: Wednesday, February 4,2026
Time: 4:00 PM ET
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that isdedicated to developing advanced vision correction solutions thatenhance the quality of life for patients. Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.
Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within thenatural lens compartment of the eye, potentially to eliminate the needfor corrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Company mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Company disclaimsany intention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events orotherwise, except as required by law.
Copyright (c) 2026 TheNewswire - All rights reserved.
NASDAQ: OTCFF
OTCFF Trading
1.98% G/L:
$0.3078 Last:
1,750 Volume:
$0.301825 Open:
